

## Company Overview

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory conditions including, serious lung infections, pulmonary hypertension and gaseous NO for the treatment of solid tumors. The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM) and COVID-19. Beyond Air have also developed a proprietary system for delivering gaseous nitric oxide at high concentrations to treat solid tumors.

## Beyond Air<sup>®</sup> Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Oct 23 2020, 8:00 AM EDT

## Beyond Air<sup>®</sup> Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit<sup>™</sup> for the Treatment of Acute Viral Pneumonia Including COVID-19

Oct 21 2020, 7:00 AM EDT

## Beyond Air<sup>®</sup> Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy

Oct 19 2020, 10:01 AM EDT

## Stock Overview

**Symbol** XAIR  
**Exchange** Nasdaq  
**Market Cap** 96.2m  
**Last Price** \$5.61  
**52-Week Range** \$3.45 - \$12.50

10/26/2020 04:00 PM EDT

## Investor Relations

LifeSci Advisors  
Corey Davis  
250 West 55th Street  
34th Floor  
New York, NY 10019  
T: 1-646-597-6989  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

## Management Team

### Steve Lisi

CEO and Chairman of the Board

### Amir Avniel

President and Chief Operating Officer

### Duncan Fatkin

Chief Commercial Officer

### Douglas Beck

Chief Financial Officer

### Frederick Montgomery, PhD

Vice President of Medical Systems

### Michael Gaul

Senior Vice President, Operations

## Beyond Air Inc.

825 East Gate Boulevard  
Suite 320  
Garden City, NY 11530

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.